Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spero TherapeuticsSPRO -0.81%70 Cash-to-Debt is 22.69 as of Mar. 2026, which is 40% above its 10-year median of 16.19. GuruFocus rates SPRO with a GF Score™ of 70/100 and a GF Value™ of $1.05 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,396 Biotechnology companies, Spero Therapeutics ranks better than 64.04% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Spero Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2026 was 22.69.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Spero Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Spero Therapeutics's Cash-to-Debt or its related term are showing as below:
SPRO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 6.49 Med: 16.19 Max: No Debt
Current: 22.69
During the past 11 years, Spero Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 6.49. And the median was 16.19.
SPRO's Cash-to-Debt is ranked better than 64.04% of 1396
companies
in the Biotechnology industry
Industry Median: 6.21
vs SPRO: 22.69
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Spero Therapeutics Cash-to-Debt Related Terms
Spero Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Spero Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a Cash-to-Debt of 22.69 as of Mar. 2026. This is 40% above median its historical median of 16.19. Over the past decade, Spero Therapeutics' Cash-to-Debt has ranged from 6.49 to 10,000.00. According to the industry distribution chart, Spero Therapeutics ranks #502 out of 1396 companies in the Biotechnology industry, placing it in the top 36%.
Is Spero Therapeutics' Cash-to-Debt too high?
Spero Therapeutics' current Cash-to-Debt of 22.69 is 40% above median its 10-year median of 16.19. Over the past 10 years, this metric has ranged from a low of 6.49 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.21. Spero Therapeutics' value of 22.69 is 265.4% above this industry median. Based on the distribution chart, Spero Therapeutics ranks #502 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spero Therapeutics has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Cash-to-Debt compare to ACRV and BSEM?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #502 out of 1396 companies for Cash-to-Debt. This puts Spero Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.21. Spero Therapeutics' value of 22.69 is 265.4% above this benchmark. Historically, Spero Therapeutics' own Cash-to-Debt has ranged from 6.49 to 10,000.00 over the past decade. While the company's 10-year median is 16.19 vs. the industry median of 6.21, Spero Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current Cash-to-Debt of 22.69 is 265.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current Cash-to-Debt is 22.69, which is 40% above median its own 10-year median of 16.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $1.24 — trading 17.6% above its estimated fair value. The current Cash-to-Debt is 22.69, which is 40% above median its 10-year median of 16.19 and 265.4% above the Biotechnology industry median of 6.21. Spero Therapeutics' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Cash-to-Debt is 22.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $1.24 is trading 17.6% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Modestly Overvalued.
Key valuation signals for SPRO:
Cash-to-Debt: 22.69 (40% above median its 10-year median of 16.19)
GF Value™: $1.05 vs. price of $1.24 (17.6% above fair value)
Industry Position: 265.4% above the Biotechnology median (#502 of 1396)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
70GF Score
Get the complete analysis for SPRO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
